ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Jiang, Tao; Chen, Jianhua; Xu, Xingxiang; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Zhang, Yaxi; Zhang, Jiao; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*; Ren, Shengxiang*南昌大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 同济大学; 重庆大学; 1
Molecular Cancer2022-1-3DOI: 10.1186/s12943-021-01479-4
25被引13阅读
引用收藏
分享

摘要

Background Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standard-of-cares for Chinese patients with advanced LUSC. However, the predictive biomarkers remain unknown. Methods Tumor tissue samples at baseline, and peripheral blood samples at baseline (pretreatment) and after two cycles of treatment (on-treatment) were prospectively collected from 270 LUSC patients from the CameL-sq study. Blood tumor mutation burden (bTMB) and its dynamics were analyzed to explore their predictive values. Results Pretreatment bTMB was not associated with objective response, PFS and OS in camrelizumab or placebo plus chemotherapy groups. Low on-treatment bTMB was associated with significantly better objective response (73.8% vs 27.8%, P < 0.001), PFS (median, 9.1 vs 4.1 months; P < 0.001) and OS (median, not reached vs 8.0 months; P < 0.001) in camrelizumab plus chemotherapy group whereas it did not correlate with objective response and PFS in chemotherapy alone group. Importantly, on-treatment bTMB level could discriminate patients of initially radiological stable disease who would long-term benefit from camrelizumab plus chemotherapy (low vs high, median OS, 18.2 vs 7.8 months; P = 0.001). Combing on-treatment bTMB and its dynamics improved the ability for predicting the efficacy of camrelizumab plus chemotherapy. Conclusion On-treatment bTMB together with its dynamics could serve as a predictive biomarker for camrelizumab plus chemotherapy in patients with advanced LUSC.

学科与关键词

关键词
immunotherapyPD-1lung squamous cell carcinomablood tumor mutational burdenbiomarker
相关
加载中…
  • Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
    Ren, Shengxiang; Chen, Jianhua; Xu, Xingxiang; Jiang, Tao; Cheng, Ying; Chen, Gongyan; Pan, Yueyin; Fang, Yong; Wang, Qiming; Huang, Yunchao; Yao, Wenxiu; Wang, Rui; Li, Xingya; Zhang, Wei; Zhang, Yanjun; Hu, Sheng; Guo, Renhua; Shi, Jianhua; Wang, Zhiwu; Cao, Peiguo; Wang, Donglin; Fang, Jian; Luo, Hui; Geng, Yi; Xing, Chunyan; Lv, Dongqing; Zhang, Yiping; Yu, Junyan; Cang, Shundong; Yang, Zeyu; Shi, Wei; Zou, Jianjun; Zhou, Caicun*Journal of Thoracic Oncology, 2022, 17(4): 544-557.被引 88
  • First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
    Zhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
  • CamreliZumab Plus Carboplatin and PemetreXed as First-Line Treatment for Advanced NonsQuamous NSCLC: EXtended Follow-Up of CameL Phase 3 Trial
    Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, YongQian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, GuangyuJournal of Thoracic Oncology, 2023, 18(5): 628-639.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Molecular Cancer
发表日期
2022-01-03
卷期
第 21 卷, 第 1 期
页码
4
DOI
10.1186/s12943-021-01479-4
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81871865, 81874036, 81972167, 82102859]; Backbone Program of Shanghai Pulmonary Hospital [FKGG1802]; Shanghai Pujiang Talent Plan [2019PJD048]; Shanghai Science and Technology Committee Foundation [19411950300]; Shanghai Key disciplines of Respiratory [2017ZZ02012]; Oncology development incentive program of Shanghai Pulmonary Hospital; Shanghai Multidisciplinary Cooperative Project for Diagnosis and Treatment of Major Diseases; Key Clinical Project Development Program of Shanghai

作者

  • J

    Jiang, Tao (第一作者)

    shanghai pulm hosp · tongji univ

  • C

    Chen, Jianhua

    hunan canc hosp

查看全部 35 位作者收起作者
  • X

    Xu, Xingxiang

  • C

    Cheng, Ying

  • C

    Chen, Gongyan

    harbin med univ

  • P

    Pan, Yueyin

    anhui prov hosp

  • F

    Fang, Yong

    zhejiang univ

  • W

    Wang, Qiming

  • H

    Huang, Yunchao

    kunming med univ

  • Y

    Yao, Wenxiu

  • W

    Wang, Rui

  • L

    Li, Xingya

    1 · zhengzhou univ

  • Z

    Zhang, Wei

    1 · nanchang univ

  • Z

    Zhang, Yanjun

  • H

    Hu, Sheng

    hubei canc hosp

  • G

    Guo, Renhua

  • S

    Shi, Jianhua

  • W

    Wang, Zhiwu

  • C

    Cao, Peiguo

  • W

    Wang, Donglin

    chongqing univ

  • F

    Fang, Jian

  • L

    Luo, Hui

    jiangxi canc hosp

  • G

    Geng, Yi

  • X

    Xing, Chunyan

    jinan cent hosp

  • L

    Lv, Dongqing

  • Z

    Zhang, Yiping

    zhejiang canc hosp

  • Y

    Yu, Junyan

    changzhi med coll

  • C

    Cang, Shundong

    henan prov peoples hosp

  • Z

    Zhang, Yaxi

  • Z

    Zhang, Jiao

  • Y

    Yang, Zeyu

  • S

    Shi, Wei

  • Z

    Zou, Jianjun

  • Z

    Zhou, Caicun (通讯)

    shanghai pulm hosp · tongji univ

  • R

    Ren, Shengxiang (通讯)

    shanghai pulm hosp · tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417